ADMA Biologics 2025 Q3 Earnings Record Net Income of $36.43M

ADMA Biologics (ADMA) reported Q3 2025 earnings on November 5, 2025, with revenue of $134.22 million, , beating estimates by $3.67 million. , reflecting strong demand for its plasma-derived biologics and operational efficiencies.

Revenue

, driven by its core ADMA BioManufacturing segment, . The Plasma Collection Centers segment reported $0 in revenue, .

Earnings/Net Income

, while net income increased by 1.4% to $36.43 million, reflecting improved operational efficiencies and strong demand.

Post-Earnings Price Action Review

The strategy of buying ADMA Biologics shares after its revenue raise on the financial report released date and holding for 30 days yielded impressive returns over the past three years, , outperforming the SPY ETF’s 2.96%. , demonstrating robust risk-adjusted performance. , likely due to market optimism about ADMA’s growth prospects. Although insider ownership is low (1.96%) and recent selling activity exists, the strategy’s returns were unaffected during the backtest period.

CEO Commentary

Adam Grossman, President and CEO, emphasized “disciplined, profitable growth” driven by FDA-approved yield-enhanced production batches, which are expected to boost margins through 2026. He highlighted record ASCENIV utilization and constructive payer negotiations for 2026 reimbursement, underscoring durable demand for plasma-derived biologics. Strategic priorities include operational efficiency, share repurchases, and advancing the SG-001 pipeline.

Guidance

. Adjusted EBITDA guidance for 2025 was reaffirmed at $235 million, . , . Long-term, .

Additional News

ADMA Biologics announced FDA lot release of yield-enhanced production batches, , . The company also highlighted progress in its SG-001 pipeline, . Additionally, ADMA’s share repurchase program and strategic capital deployment were reiterated as priorities, .

Image Placeholder